Other meanings of Precision oncology
Cancer medicine
Precision oncology is personalized cancer treatment guided by a tumor’s genetic and molecular characteristics. It combines tumor profiling with clinical evidence to identify therapies more likely to benefit a particular patient, while recognizing that a molecular match does not guarantee response. The approach can also identify inherited cancer-risk variants, resistance mechanisms, and opportunities for clinical-trial enrollment.1
Precision oncology matches cancer treatment to measurable features of an individual tumor rather than relying only on its anatomical site. Those features may include DNA mutations, gene fusions, copy-number changes, gene expression, protein markers, or characteristics of the tumor immune environment.1 The relevant alterations can be drivers that help sustain malignant growth, passenger changes with little functional effect, or inherited variants that affect cancer risk and drug handling.
Testing usually begins with a biopsy, although blood-based liquid biopsy can sometimes detect circulating tumor DNA when tissue is limited or when repeated sampling is useful. Results are interpreted alongside tumor type, stage, previous treatments, overall health, and the strength of clinical evidence. Precision medicine therefore supplements pathology and clinical judgment; it does not replace them.
The central task is to distinguish an actionable biomarker from a merely interesting molecular finding. A molecular tumor board or oncology team may compare sequencing results with approved indications, clinical guidelines, drug labels, and ongoing trials. A companion diagnostic is an especially important case: the test is linked to the safe and effective use of a particular medicine and may be required before treatment.
Some therapies target oncogenic alterations directly, while others exploit broader vulnerabilities such as defective DNA repair or high microsatellite instability. Immunotherapies can be selected using markers such as PD-L1 expression or mismatch-repair deficiency, although these markers are imperfect. The NCI-MATCH trial illustrated a basket-trial model in which patients were assigned according to genomic alterations rather than cancer location, helping evaluate targeted treatments across multiple tumor types.2
Precision oncology is limited by tumor heterogeneity, incomplete evidence, and the rapid evolution of treatment resistance. A single biopsy may miss subclones elsewhere in the cancer, and a detected alteration may lack a matched drug or have evidence only from a small study. Tumors can acquire secondary mutations, activate bypass pathways, or change their immune environment, causing an initially effective therapy to stop working.
Access is also uneven. Comprehensive sequencing, specialist interpretation, trial participation, and expensive medicines are not equally available across health systems or communities. Genetic findings can raise privacy and family implications when they suggest an inherited predisposition rather than a tumor-only change. Careful consent, genetic counseling when appropriate, and attention to ancestry-related gaps in genomic databases are therefore part of responsible implementation.
Precision oncology extends beyond finding a single mutation with a matching pill. The same molecular result may guide prognosis, surgery or radiation decisions, dose selection, monitoring, or referral to a trial; it may also reveal that a tumor has a tissue-agnostic treatment opportunity. The Cancer Genome Atlas helped establish large reference maps of genomic and molecular changes across cancer types, making cross-tumor comparisons more practical.
Negative results can be informative but are not equivalent to proof that no target exists: assays differ in coverage, sample quality can be poor, and some relevant biology is epigenetic, RNA-based, or protein-level rather than a DNA sequence variant. Testing can also be repeated at relapse because the molecular profile may have changed. These edge cases explain why precision oncology is best understood as an iterative clinical process rather than a one-time sequencing procedure.
Progress in precision oncology depends on linking molecular data to outcomes from well-designed clinical studies. Randomized trials remain essential for determining whether biomarker selection improves survival or quality of life, while adaptive and basket designs can evaluate rare alterations more efficiently. Public databases, standardized variant interpretation, and broad access to trial-matching services help convert laboratory observations into usable evidence.
Regulators have increasingly recognized diagnostics as part of the treatment pathway, but evidence standards vary according to the claim being made. A test may be analytically accurate yet clinically unproven for selecting therapy. The field therefore combines genomics with pharmacology, pathology, immunology, bioinformatics, and health-policy research, with the practical goal of delivering the right treatment to the right patient without overstating what a molecular result can predict.
Molecular findings should be interpreted by qualified oncology professionals in the context of the patient’s complete clinical record; a biomarker match is not a guarantee of treatment benefit.
Help improve the encyclopedia. Reports go straight to the site manager.